title: [Effect of polymorphisms of cytochrome P450 and apolipoprotein E genes on therapeutic efficacy of statins].
abstract: Statins are widely used in clinical practice for lowering of levels of atherogenic blood plasma lipids and treatment of atherosclerosis. Variability of response of the body to these drugs might be determined by genetic factors (gene polymorphisms) related to metabolism of drugs. Among them central place belongs to enzymes of subfamily 3A of cytochrome P450 (CYP). In this review we present results of studies assessing effect of various allele variants of CYP3A4 and CYP3A5 on efficacy and tolerability of atorvastatin, lovastatin,, and simvastatin in different populations of patients. We also present data on populational frequency of genetic polymorphisms under study. In addition we cover the problem of possible influence of apoE genotype on efficacy of statins. The available data do not allow yet to recommend pharmacogenetic testing for wide clinical practice.
authors.forename: P P
authors.initials: PP
authors.lastname: Malyshev
authors.forename: Z Iu
authors.initials: ZIu
authors.lastname: Mal'makova
authors.forename: A N
authors.initials: AN
authors.lastname: Meshkov
authors.forename: V V
authors.initials: VV
authors.lastname: Kukharchuk
mesh_terms: D001057:Apolipoproteins E / Q000235:genetics*; D050197:Atherosclerosis / Q000235:genetics / Q000628:therapy; D001682:Biological Availability; D001711:Biotransformation / Q000235:genetics; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D004351:Drug Resistance / Q000235:genetics*; D005820:Genetic Testing / Q000600:supply & distribution; D005828:Genetics, Population; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000493:pharmacokinetics*; D006949:Hyperlipidemias / Q000235:genetics / Q000628:therapy; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
chemical_list: D001057:Apolipoproteins E; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D051544:Cytochrome P-450 CYP3A